Compile Data Set for Download or QSAR
Report error Found 102 Enz. Inhib. hit(s) with all data for entry = 11373
TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610623(US11713307, Compound 1.071)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610622(US11713307, Compound 1.070)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610621(US11713307, Compound 1.069)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610628(US11713307, Compound 1.076)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610627(US11713307, Compound 1.075)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610626(US11713307, Compound 1.074)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610625(US11713307, Compound 1.073)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610632(US11713307, Compound 1.079)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610631(US11713307, Compound 1.078)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610630(US11713307, Compound 1.077)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610637(US11713307, Compound 1.084)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610636(US11713307, Compound 1.083)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610635(US11713307, Compound 1.082)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610634(US11713307, Compound 1.081)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610608(US11713307, Compound 1.056)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610607(US11713307, Compound 1.055)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610606(US11713307, Compound 1.054)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610605(US11713307, Compound 1.053)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610612(US11713307, Compound 1.060)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610611(US11713307, Compound 1.059)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610609(US11713307, Compound 1.057)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610616(US11713307, Compound 1.064)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610615(US11713307, Compound 1.063)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610614(US11713307, Compound 1.062)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610613(US11713307, Compound 1.061)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610620(US11713307, Compound 1.068)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610619(US11713307, Compound 1.067)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610618(US11713307, Compound 1.066)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610617(US11713307, Compound 1.065)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610656(US11713307, Compound 1.102)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610655(US11713307, Compound 1.101)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610641(US11713307, Compound 1.088 | US20240115682, Compou...)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610640(US11713307, Compound 1.087)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610639(US11713307, Compound 1.086)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610638(US11713307, Compound 1.085)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610645(US11713307, Compound 1.092)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610644(US11713307, Compound 1.091)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610643(US11713307, Compound 1.090)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610642(US11713307, Compound 1.089)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610650(US11713307, Compound 1.096)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610649(US11713307, Compound 1.095)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610648(US11713307, Compound 1.094)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610647(US11713307, Compound 1.093)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610654(US11713307, Compound 1.100)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610653(US11713307, Compound 1.099)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610652(US11713307, Compound 1.098)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610651(US11713307, Compound 1.097)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610558(US11713307, Compound 1.008 | US20240115682, Compou...)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610557(US11713307, Compound 1.007)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

TargetProgrammed cell death 1 ligand 1(Human)
Chemocentryx

US Patent
LigandPNGBDBM610556(US11713307, Compound 1.006 | US20240115682, Compou...)
Affinity DataIC50: 10nMAssay Description:96 Well plates were coated with 1 μg/mL of human PD-L1 (obtained from R&D) in PBS overnight at 4° C. The wells were then blocked with 2% BSA in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/4/2023
Entry Details
US Patent

Displayed 1 to 50 (of 102 total ) | Next | Last >>
Jump to: